Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.
暂无分享,去创建一个
Adrian F Hernandez | Anita Deswal | Christopher M O'Connor | Josef Stehlik | Kevin J Anstrom | Thomas P Cappola | Eric J Velazquez | Javed Butler | Douglas L Mann | K. Anstrom | C. O'connor | J. Rouleau | E. Braunwald | G. Felker | J. Butler | Adrian F. Hernandez | D. Mann | L. Stevenson | M. LeWinter | R. Starling | K. Margulies | W. Tang | S. McNulty | S. Goldsmith | B. Borlaug | M. Redfield | M. Konstam | B. Bart | D. Bull | T. Cappola | E. Ofili | E. Velazquez | E. O'meara | J. Stehlik | M. Semigran | V. Dávila-Román | G. Huggins | M. Givertz | Lynne W Stevenson | Barry A Borlaug | Margaret M Redfield | David A Bull | Eugene Braunwald | Kerry L Lee | Kenneth B Margulies | G Michael Felker | Randall C Starling | Michael M Givertz | Marvin A Konstam | M. Shah | Marc J Semigran | Horng H Chen | Steven R Goldsmith | Bradley A Bart | Martin M LeWinter | Gordon S Huggins | Jean L Rouleau | Eileen O'Meara | W H Wilson Tang | Raphael E Bonita | Elizabeth O Ofili | Víctor G Dávila-Román | Steven E McNulty | Monica R Shah | R. Bonita | A. Deswal | Horng H. Chen | E. O’Meara | Kerry L. Lee | Adrian F. Hernandez | Horng H. Chen | Martin M. LeWinter | Adrian F. Hernandez | Lynne W. Stevenson | Steven R. Goldsmith | David A. Bull | Marvin A. Konstam | Gordon S. Huggins | Jean L. Rouleau | W. Tang | Randall C. Starling | Christopher M. O’Connor | Raphael E. Bonita | Elizabeth O. Ofili | Douglas L. Mann | Eric J. Velazquez | Monica R. Shah | Martin M Lewinter | W. H. W. Tang | Kerry L. Lee | Martin M. Lewinter | W. W. Tang
[1] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[2] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[3] V. Hasselblad,et al. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). , 2013, Journal of the American College of Cardiology.
[4] K. Anstrom,et al. Targeting the Kidney in Acute Heart Failure: Can Old Drugs Provide New Benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) Trial , 2013, Circulation. Heart failure.
[5] M. Walsh,et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. , 2013, Journal of cardiac failure.
[6] P. Ponikowski,et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.
[7] Piotr Ponikowski,et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.
[8] K. Anstrom,et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.
[9] R. Nishimura,et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. , 2012, Journal of the American College of Cardiology.
[10] S. Werns. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .
[11] Adrian F Hernandez,et al. Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.
[12] B. Kozłowski. Summary of the article: Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. Engl J Med, 2011; 364: 797–805 , 2011 .
[13] Dirk Westermann,et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. , 2010, Journal of cardiac failure.
[14] P. Ponikowski,et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.
[15] Nancy M Albert,et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.
[16] Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.
[17] J. Burnett,et al. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. , 2009, Journal of the American College of Cardiology.
[18] M. Schnitzler,et al. Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database. , 2008, American heart journal.
[19] D. Hodge,et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. , 2008, Journal of cardiac failure.
[20] U. Elkayam,et al. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action , 2008, Circulation.
[21] R. Witteles,et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. , 2007, Journal of the American College of Cardiology.
[22] T. Sundt,et al. Low Dose Nesiritide and the Preservation of Renal Function in Patients With Renal Dysfunction Undergoing Cardiopulmonary-Bypass Surgery: A Double-Blind Placebo-Controlled Pilot Study , 2007, Circulation.
[23] G. Fonarow,et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. , 2007, Journal of cardiac failure.
[24] M. Shlipak,et al. Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2006, Circulation.
[25] M. Redfield,et al. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. , 2006, Journal of the American College of Cardiology.
[26] D. Siscovick,et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.
[27] Joseph Beyene,et al. Meta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death , 2005, Annals of Internal Medicine.
[28] K. Aaronson,et al. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.
[29] M. Fisher,et al. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine , 2004, Circulation.
[30] C. O'connor,et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. , 2003, American heart journal.
[31] H. Krumholz,et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? , 2002, Journal of cardiac failure.
[32] C. O'connor,et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. , 2002, Journal of cardiac failure.
[33] James B. Young. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .
[34] A. Charlesworth,et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.
[35] M. Domanski,et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.
[36] J. Lachin. Worst-rank score analysis with informatively missing observations in clinical trials. , 1999, Controlled clinical trials.
[37] Horng H. Chen,et al. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. , 1999, Proceedings of the Association of American Physicians.
[38] Y. Moshkovitz,et al. Increased toxicity of high‐dose furosemide versus low‐dose dopamine in the treatment of refractory congestive heart failure , 1997, Clinical pharmacology and therapeutics.
[39] P. Varriale,et al. The benefit of low‐dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: Does it protect renal function? , 1997, Clinical cardiology.
[40] G. Chertow,et al. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. , 1996, Kidney international.
[41] T. LeJemtel,et al. Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure. , 1985, Circulation.
[42] R. Mcdonald,et al. SODIUM DIURESIS PRODUCED BY DOPAMINE IN PATIENTS WITH CONGESTIVE HEART FAILURE. , 1963, The New England journal of medicine.